Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8NC06
UPID:
ACBD4_HUMAN
Alternative names:
-
Alternative UPACC:
Q8NC06; D3DX64; Q8IUT1; Q9H8Q4
Background:
Acyl-CoA-binding domain-containing protein 4 plays a crucial role in cellular metabolism by binding medium- and long-chain acyl-CoA esters. This function suggests its involvement in the intracellular transport and regulation of acyl-CoA esters, essential components in lipid metabolism and energy production.
Therapeutic significance:
Understanding the role of Acyl-CoA-binding domain-containing protein 4 could open doors to potential therapeutic strategies. Its pivotal role in lipid metabolism and energy production makes it a promising target for addressing metabolic disorders.